Advancing new potential treatments for certain GI diseases affecting millions of patients in need

  • Product
  • Indication
  • PHASE I
  • PHASE II
  • PHASE III
  • Approval
  • Linzess® Partner
  • Launched 12/12

  • linaclotide Partner
  • IBS-C abdominal symptoms in adults (not an indication, additional data that may be added to the label)

  • Phase IIIb expected Mid-2019
  • linaclotide Partner
  • Functional constipation pediatrics

  • IW-3718
  • Persistent GERD

  • Phase III results expected 2H 2020
  • MD-7246 Partner
  • Abdominal pain associated with IBS with diarrhea (IBS-D)

  • Phase II trial expected to initiate 2Q 2019

Represents current phase of development, does not correspond to the initiation or completion of a particular phase.

Status of key development programs as of February 28, 2019.

Click here for LINZESS® full US Prescribing Information including BOXED WARNING.

Copyright © 2019, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.